The DOI matches its Crossref record.
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co
Open accessAbstract
BACKGROUND: The cytokine interleukin-31 (IL-31) is considered to be responsible for the development of pruritus in humans. At present, no available evidence has been provided on the safety and efficacy of blocking the IL-31 signal in humans for the amelioration of pruritus in atopic dermatitis (AD). CIM331 is a humanized antihuman IL-31 receptor A (IL-31RA) monoclonal antibody, which binds to IL-31RA to inhibit subsequent IL-31 signalling. OBJECTIVES: To assess the tolerability, safety, pharmacokinetics and preliminary efficacy of CIM331 in healthy Japanese and white volunteers, and Japanese patients with AD. METHODS: In this randomized, double-blind, placebo-controlled phase I/Ib study, CIM331 was administered in a single subcutaneous dose. The primary outcomes were safety and tolerability; the exploratory analysis was efficacy. RESULTS: No deaths, serious adverse events (AEs) or discontinuations due to AEs were reported in any part of the study. No dose-dependent increase in the incidence of AEs occurred in any part of the study. In healthy volunteers, all AEs occurred once in the placebo groups, and increased creatine phosphokinase was more common in the CIM331 groups. In patients with AD, CIM331 reduced pruritus visual analogue scale score to about -50% at week 4 with CIM331 compared with -20% with placebo. CIM331 increased sleep efficiency and decreased the use of hydrocortisone butyrate. CONCLUSIONS: A single subcutaneous administration of CIM331 was well tolerated in healthy volunteers and patients with AD. It decreased pruritus, sleep disturbance and topical use of hydrocortisone. CIM331 may become a novel therapeutic option for AD by inhibiting IL-31.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Self-citationTrial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917006 · Cited by 361
Self-citationAtopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies
Furue, M., Chiba, T., Tsuji, G., Ulzii, D., Kido-Nakahara, M., Nakahara, T., & Kadono, T. (2017) · Allergology International · doi:10.1016/j.alit.2016.12.002 · Cited by 324
Self-citationMuraro, A., Lemanske, R. F., Hellings, P. W., Akdis, C. A., Bieber, T., Casale, T. B., Jutel, M., Ong, P. Y., Poulsen, L. K., Schmid-Grendelmeier, P., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.010 · Cited by 284
Physiology and Pathophysiology of Itch
Cevikbas, F., & Lerner, E. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00017.2019 · Cited by 282
Silverberg, J. I., Pinter, A., Pulka, G., Poulin, Y., Bouaziz, J.-D., Wollenberg, A., Murrell, D. F., Alexis, A., Lindsey, L., Ahmad, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.013 · Cited by 271
Kabashima, K., Furue, M., Hanifin, J. M., Pulka, G., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Nakano, M., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.03.018 · Cited by 248
Self-citationEmerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis
Furue, M., Yamamura, K., Kido‐Nakahara, M., Nakahara, T., & Fukui, Y. (2018) · Allergy · doi:10.1111/all.13239 · Cited by 240
Self-citationRerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-017-0044-7 · Cited by 187
Self-citationInterleukin‐31 and interleukin‐31 receptor: New therapeutic targets for atopic dermatitis
Nakashima, C., Otsuka, A., & Kabashima, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13533 · Cited by 154
Self-citationNovel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
The pathology of type 2 inflammation-associated itch in atopic dermatitis
Moniaga, C. S., Tominaga, M., & Takamori, K. (2021) · Diagnostics · doi:10.3390/diagnostics11112090 · Cited by 28
Metadata
- Authors
- Nemoto, O., Furue, M., Nakagawa, H., Shiramoto, M., Hanada, R., Matsuki, S., Imayama, S., Kato, M., Hasebe, I., Taira, K., Yamamoto, M., Mihara, R., Kabashima, K., Ruzicka, T., Hanifin, J., & Kumagai, Y.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12-19
- Volume
- 174
- Issue
- 2
- Pages
- 296-304
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W1947587912
- Cited by
- 193
- References
- 0
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.